C. H. Robinson Worldwide, Inc. (CHRW) · Nov 20, 2026 · New debt
$500M term loan — $500M delayed-draw commitment for RXO financing
C.H. Robinson’s new debt financing supports the planned RXO acquisition, adding execution certainty without changing the deal’s core economics.
C.H. Robinson is in the middle of a planned $5.8 billion acquisition of RXO, intended to create a broader logistics platform, add roughly $300 million of run-rate cost synergies and support a return to 1.75x–2.25x net leverage by year-end 2028. The deal is expected to close in the first half of 2027 and was already backed by up to $4.5 billion of committed bridge financing.
This filing formalizes $500 million of acquisition financing, not a new strategic move. The delayed-draw facility permits a single borrowing on the RXO closing date and can be used to fund the acquisition, refinance RXO debt and pay related transaction costs. 〔0〕
| Facility / covenant | Current figure | Key comparison |
|---|---|---|
| Delayed-draw term loan commitment (Agreement) | $500M | — |
| Borrowing structure (Section 2.1) | 1 draw | Closing date |
| Initial net leverage ceiling (Section 6.15) | 4.25x | 3.75x thereafter |
| Term SOFR margin, Level III (Pricing Schedule) | 1.00% | Base rate margin: 0.125% |
| Ticking fee, Level III (Pricing Schedule) | 0.090% | Begins February 1, 2027 |
The facility improves funding certainty but does not prove the transaction is funded or closed. The commitment is conditional on the RXO acquisition being completed and RXO’s existing financing being refinanced concurrently. 〔1〕 〔2〕
Most of the financing architecture was already public. The acquisition announcement disclosed fully underwritten bridge financing, while an earlier November amendment expanded the revolving facility and adjusted leverage terms to accommodate the transaction. This filing supplies a more specific $500 million term-loan commitment, but it does not change the purchase price, expected synergies, leverage target or closing timetable.
Bottom line: This is execution progress around the RXO transaction, not a rewrite of C.H. Robinson’s story. It modestly reduces financing uncertainty, but the market already knew the acquisition would require substantial new debt, so the filing is largely confirmatory rather than a fresh business signal.
RXO shareholder and regulatory approvals; closing targeted for first half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!